By Karen Roman Sequana Medical NV (BRU: SEQUA.BR) said it successfully implanted the alfapump device for treatment of recurrent or refractory ascites due to liver cirrhosis in two patients at the University of Pennsylvania. The alfapump is the first FDA-approved...

By Daniella Parra March Bio is developing MB-105, a first-in-class autologous CD5-targeted CAR-T cell therapy for relapsed/refractory T-cell lymphoma and other CD5-positive hematologic malignancies, they said. The company said the therapy employs a proprietary CAR design that enables selective targeting of...

Exec Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Chris Searles, co-founder and Chief Executive Officer, and Trevor Smith, co-founder and Chief Technology Officer of DxCheck. The in-person interview was joined by Editor-in-Chief John Jannarone and...

IPO Edge hosted a fireside chat on Dec. 8 from the Nasdaq Marketsite with Christer Rosen, Chairman and Chief Executive Officer, and Alison Silva, President and Chief Business Officer of Jupiter Neurosciences, Inc. (Nasdaq: JUNS). The in-person interview was joined by...

By Daniella Parra ReAlta Life Sciences’ Pegtarazimod demonstrated significant clinical improvement and reduction in inflammatory markers in patients with lower gastrointestinal aGvHD, the company said. Clinical MAGIC stage improvement observed for 6 of 6 patients with steroid-refractory aGvHD, with 4...

By Karen Roman March Biosciences said it appointed Gurpreet Ratra, Ph.D., as Chief Business Officer. Dr. Ratra has more than 25 years of experience in the life science industry including cell and gene therapy, as well as equity research leadership, the...

By Karen Roman Acumen Pharmaceuticals, Inc. (Nasdaq: ABOS) said it is presenting new research at the 18th Annual Clinical Trials on Alzheimer’s Disease (CTAD) Conference, being held on December 1-4, 2025, in San Diego, California. Acumen and JCR Pharmaceuticals are...

By Karen Roman ReAlta Life Sciences, Inc. announced the designation of Howard Berman, Ph.D., as Executive Chairman of its Board of Directors, effective immediately. “His proven track record in advancing innovative immunology-based therapies and creating value, positions ReAlta for disciplined growth...

By Daniella Parra Sequana Medical said the first implantation of the alfapump in the U.S. at Mount Sinai Hospital received FDA approval for the treatment of recurrent or refractory ascites due to liver cirrhosis. Sequana is working to relieve patients...

By Karen Roman Imviva Biotech said it will present its progress in allogenic cell therapy candidates in two oral presentations and five poster presentations at the 67th American Society of Hematology (ASH) Annual Meeting, to be held on December 6-9,...